On April 12, the New YorkSenate Health Committee rejected S.B. 2855, legislation MRA had lobbied against, which would have restricted marketing research incentives for healthcare providers.

S.B. 2855 would have required manufacturers of prescription drugs to report their annual marketing costs to the department of health. It defined "marketing" as "advertising and promotional activities for prescription drugs dispensed in this state” “with regard to all providers of healthcare services… including health maintenance organizations", including "all expenses associated with food, entertainment and gifts valued at more than seventy-five dollars, and anything provided to a health care professional for less than market value."

Given that incentives for health care providers participating in marketing research studies could have been included, MRA sought to defeat S.B. 2855 ... and succeeded.